BioCryst Pharmaceuticals have announced that Health Canada accepted their new drug submission for ORLADEYO® (berotralstat) for review for the prevention of recurring attacks in patients aged 12 years and older who have hereditary angioedema (HAE). Similarly, Swissmedic has also accepted ORLADEYO’s marketing authorization for review. ORLADEYO is currently the only oral drug that aims to prevent frequent attacks of hereditary angioedema (HAE) in both adult and pediatric patients over 12 years. Characterized by its ability to decrease the activity of plasma kallikrein, the patient takes one capsule of ORLADEYO per day.
Read more here.
More on: News Regulatory